Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Post by RazeKreationson Nov 08, 2022 1:44pm
196 Views
Post# 35082785

1st Podcast Nov 16th

1st Podcast Nov 16th
We are excited to finally announce the LAUNCH DATE of our upcoming podcast series....Diagnostics: Beyond the Lab!
On this podcast we will feature guests from the scientific and health industry discussing innovations in their respective fields. Tune in to our #FIRST EPISODE of the series on 16th November, 2022!
To learn more about #Microbix, visit us at: https://lnkd.in/d5Pyd2kV 
For details, #contactus at: bit.ly/3Bs4nts
#Podcast #Diagnostics #BeyondtheLab #Biotechnology #Microbix

Meet one of our first guests on our 1st Episode of Diagnostics: Beyond the Lab, Larry Vaughan!
Larry holds a bachelor's degree in Genetics and a Ph.D. in Molecular Microbiology, both from Trinity College Dublin. He began his career in vet vaccines, leading a molecular development team at BioResearch Ireland, based on the Trinity campus. He moved his career to the US in 1998, joining Corning’s Life Sciences Division, developing products for Pharma research. His desire to return to infectious disease research led him to join Digene Corporation, the first HPV diagnostics company, in 2006. 
After the company was acquired by QIAGEN, he moved to his current company, BD (Becton, Dickinson and Company), to head up their R&D assay development group. This group developed the BD Onclarity™ HPV Assay that gained FDA approval in 2018 and additional approval for extended genotyping in 2020. He moved to Medical Affairs in 2019, as a Director of Scientific Affairs.

<< Previous
Bullboard Posts
Next >>